1. Pink Sheet

Genetic Exposé Of Ovarian Cancer Prompts Radical Rethink Of Trial Design

 
• By Emily Hayes

Whereas Phase III cancer trials are currently randomized and involve hundreds of patients, some experts say small trials with from 20 to 50 patients make more sense for targeted drugs in ovarian cancer, considering the genetic diversity of this already uncommon disease.

Experts are rethinking trial designs for targeted drugs in ovarian cancer in light of the recent findings of the Cancer Genome Atlas project, which has provided a window into the tremendous genetic diversity of the uncommon disease.

Funded by the National Institutes of Health’s National Cancer Institute and National Human Genome Research Institute, The...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D